Skip to main content
. 2014 Jul 8;111(3):486–496. doi: 10.1038/bjc.2014.152

Figure 6.

Figure 6

Knockdown of PD2 with drug treatment in SP cells. (A) Seven days of gemcitabine treatment followed by transient knockdown (72 h) of PD2 was carried out in SW1990-SP cells. Knockdown of PD2 with simultaneous gemcitabine treatment in cancer stem cells (SP) decreased the viability of SP cells and changed its phenotype. (B) FACS-apoptosis analysis with annexin V and propidium iodide staining showed an increased percentage of cell death (30.1%) in PD2 knockdown SP cells along with gemcitabine treatment compared with control cells (18.8%). (C) RT–PCR results showed that knockdown of PD2 downregulates the levels of CD133 and the multidrug resistance 2 (MDR2) gene. Western blot results showed a decrease in the expression of CD133 protein in PD2 knockdown cells. GAPDH and β-actin served as an expression control. Fold change of band intensity is mentioned in the RT–PCR and western blot results.